Alicia Alford, a recent graduate of the BULLS Life Sciences Academy and Durham Technical Community College, said Accelerate NC had helped her get her new “big girl job” as a Manufacturing Associate I ...

Q1 2025 Earnings Call Transcript May 14, 2025 PDS Biotechnology Corporation beats earnings expectations. Reported EPS is ...

Chemomab Therapeutics Ltd.(Nasdaq:CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced ...

CHICAGO, May 15, 2025--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American ... about the efficacy data from the Phase 2 THIO-101 clinical trial was accepted for poster presentation at the 2025 ...

YUFLYMA® (adalimumab-aaty) is a high-concentration (100mg/mL) and citrate-free formulation of Humira® (adalimumab) biosimilar ...

Labroots’ virtual events enable individuals worldwide to connect and engage in groundbreaking scientific research from your ...

Repeated positive recommendation from Data Safety Monitoring Board ("DSMB") of pivotal Phase 3 study for lead clinical ...

MAIA Biotechnology, Inc. (MAIA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). CHICAGO, March 20, 2025--MAIA ...

Company's first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammationNovel ...

This work was carried out within an international consortium supported by the U.S. Food and Drug Administration (FDA). The results of the study -- published in Angewandte Chemie International ...

Cellular agriculture represents a groundbreaking frontier in food production technology, with the potential to revolutionize the way we generate ...